IMC Chicago
CRCA

IMC Chicago’s ProShares Ultra CRCL CRCA Stock Holding History

IMC Chicago’s Portfolio CRCA Stock Details CRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$425K Buy
+10,300
New +$428K ﹤0.01% 4220

Other funds holding CRCA

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

IMC Chicago's CRCA Position: Q1 2026 in Review

IMC Chicago sold out of ProShares Ultra CRCL (CRCA) in Q1 2026, closing a stake of 5,404 shares — an estimated $224K sold.

IMC Chicago first reported a position in CRCA in Q4 2025 and held it in 1 quarter. The position peaked at $218K in Q4 2025. 7 funds tracked by Wall St. Rank hold CRCA as of Q1 2026.

  • IMC Chicago reported no remaining ProShares Ultra CRCL position as of Q1 2026 after selling out during the quarter.
  • IMC Chicago sold 5,404 ProShares Ultra CRCL shares in Q1 2026, an estimated $224K.
  • IMC Chicago first reported a position in ProShares Ultra CRCL in Q4 2025 and held it in 1 quarter.
  • IMC Chicago's ProShares Ultra CRCL position peaked at $218K in Q4 2025.
  • 7 funds tracked by Wall St. Rank held ProShares Ultra CRCL as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.